AVXL
Anavex Life Sciences Corp.
There isn't enough reported data to score AVXL yet.
AVXL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AVXL's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
AVXL PE Valuation
AVXL has no meaningful PE right now: it lost money over the past year.
AVXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect AVXL's losses to grow, with revenue holding steady.
AVXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.15 | +$0.42 |
| Q1 2026 | -$0.39 | +$0.16 |
| Q4 2025 | -$0.46 | +$0.09 |
| Q3 2025 | -$0.54 | -$0.02 |
| Q2 2025 | -$0.57 | -$0.06 |
| Q1 2025 | -$0.55 | -$0.04 |
| Q4 2024 | -$0.55 | -$0.01 |
| Q3 2024 | -$0.52 | +$0.08 |
AVXL is still losing money, but far less than before: $0.15 per share over the past year, against $0.60 at its worst in late 2023.
AVXL Quarterly Revenue
AVXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.1M | +$3.4M |
| Q1 2026 | -$4.4M | +$1.4M |
| Q4 2025 | -$7.2M | +$5M |
| Q3 2025 | -$8.6M | -$1.9M |
| Q2 2025 | -$12.5M | -$7.3M |
| Q1 2025 | -$5.9M | +$5.8M |
| Q4 2024 | -$12.1M | -$4.8M |
| Q3 2024 | -$6.7M | -$808.4K |
AVXL has burned cash in almost every quarter: −$29M over the past year, against −$37M the year before.
AVXL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +3.6M shares |
| 1 year | +8.9% | +7.6M shares |
| 3 years | +15% | +11.8M shares |
| 5 years | +35% | +24.1M shares |
| Available history | +89% | +43.8M shares |
AVXL has 93M diluted shares, up 8.9% from a year ago.
AVXL Net Leverage
AVXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AVXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.4 | Oversold |
| Stochastic | 1.9 | Oversold |
AVXL's weekly RSI is 25 (oversold) and its Stochastic is 2 (oversold).
AVXL PE vs Healthcare Sector
AVXL has no meaningful PE right now: it lost money over the past year.
AVXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.46 | 32% below |
| 20 week MA | $2.26 | 56% below |
| 50 week MA | $3.10 | 68% below |
| 100 week MA | $6.05 | 84% below |
| 200 week MA | $6.49 | 85% below |
AVXL is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
AVXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.54 | $5.75 | +126% |
| 2021 | $5.75 | $19.5 | +239% |
| 2022 | $19.5 | $8.45 | -57% |
| 2023 | $8.45 | $9.31 | +10% |
| 2024 | $9.31 | $12.1 | +30% |
| 2025 | $12.1 | $3.64 | -70% |
| 2026 YTD | $3.64 | $0.99 | -73% |
AVXL's yearly returns have swung widely, from +239% in 2021 to −70% in 2025. It's down 73% so far in 2026.